Stretta RF Therapy meets endpoints for GERD - Mederi

A newly-published clinical study evaluating 217 patients with gastroesophageal reflux disease (GERD) for ten years after receiving Stretta RF Therapy, from Mederi Therapeutics, showed that the study successfully reached all primary and secondary outcomes, with significant improvements in, GERD-health-related quality of life (HRQL) scores, patient satisfaction, and PPI use with results being durable at 10 years in the majority of patients. Normalization of GERD HRQL scores was achieved in 72 percent of patients (primary endpoint 70 percent).

It also showed a 50 percent or greater reduction in PPI use occurred in 64 percent of patients - 41 percent eliminated PPIs entirely. Additionally the study found a regression in Barrett's metaplasia, and no adverse effects of treatment, confirming the procedure's long-term safety. See: "Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later," Mark Noar et al. Surgical Endoscopy online February edition DOI 10.1007/s00464-014-3461-6